A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This study is a phase I, open-label, single-arm, dose escalation trial to determine the
safety and activity of lenalidomide combined with lintuzumab in patients with MDS. Small
groups of 3-6 patients will be treated with pre-specified doses of lenalidomide and
lintuzumab and will receive 3-week cycles of combination therapy.